Mr. Turner has 30 years of experience as an entrepreneur, operating manager and investor. He founded Montreux and has been a General Partner and Managing Member since 1993.
Mr. Turner has invested in companies across consumer, healthcare services, pharmaceuticals and technology companies. Some of his previous investments includes Paymap (acquired by First Data Corp), Peapod (IPO; acquired by Royal Ahold), and Great Lakes Health Plan (acquired by United Healthcare). Mr. Turner is a member of the board of directors of Avantis Medical, GC Aesthetics, Moksha8 and Pure Life Renal. Mr. Turner previously served as Montreux's representative to the board of directors of Glaukos (NYSE: GKOS), Tobira Therapeutics, Epirus Biopharmaceuticals (NASDAQ: EPRS), Renal CarePartners (sold to Ambulatory Services of America 2011), Cerexa (sold to Forest Laboratories, 2007), NovaCardia (sold to Merck, 2007), and Peninsula Pharmaceuticals (sold to Johnson & Johnson, 2005).
Mr. Turner started his career with Price Waterhouse in the high technology group. He later became the founding Chief Financial Officer of Oclassen Pharmaceuticals, a specialty pharmaceutical company focused in dermatology, which merged with Watson Pharmaceuticals (NYSE: WPI) in 1997. Immediately prior to founding Montreux, Mr. Turner was a Principal in the Turnaround Group for Berkeley International.
In addition to his activities at Montreux, Mr. Turner is a member of the Advisory Board of the Lester Center at the Haas School of Business at the University of California, Berkeley.
He holds a B.S. from California State University, Sacramento and attended the M.B.A. program at the Haas School of Business at the University of California, Berkeley, where he has established the Turner Fellowship. Mr. Turner is a Certified Public Accountant.